Trade Gilead ^GILD

Cheap version of game-changing HIV preventive drug granted approval by US authorities

Gilead's Livdelzi Achieves 75% ALP Normalization In Phase 3 IDEAL Study; Stock Down

Promising Biotech Stocks To Watch Now - November 5th - Markets Daily

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC) | Morningstar

Gilead Sciences (NASDAQ:GILD) Hits New 1-Year High - What's Next?

Gilead Sciences (GILD) Presented 18 Month CAR T Data At ASH 2026

Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe. - AOL

Gilead Sciences, Inc. $GILD Stock Sold by MH & Associates Securities Management Corp ADV

Gilead Sciences, Inc. $GILD Stock: AIA Group Ltd Reduces Stake

Biotech Stocks To Keep An Eye On - November 4th - Markets Daily

Gilead Sciences, Inc. $GILD Stock Purchased by Rakuten Investment Management Inc.

Gilead Sciences, Inc. $GILD Stock Purchased by Provenance Wealth Advisors LLC

Near 52-Week Highs: Is This 88% Margin Biotech Still a Bargain?

Critical Survey: Gilead Sciences (NASDAQ:GILD) versus Xenetic Biosciences (NASDAQ:XBIO) - Stock Observer

BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo

Gilead Sciences Sees Unusually High Options Volume (NASDAQ:GILD)

6,170 Shares of Gilead Sciences, Inc. $GILD Bought by TSG Advice Partners LLC

Gilead Sciences, Inc. $GILD Stock Holdings Lifted by BOCHK Asset Management Ltd

Gilead Sciences Launches Global Capability Center in Bengaluru, ETGCC

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,000 Shares of Stock

Reply to: 'Interpreting surgical consolidation in oligometastatic gastro-oesophageal cancer'

Insider Selling: Gilead Sciences (NASDAQ:GILD) CEO Sells 15,881 Shares of Company Stock - Stock Observer

Gilead Sciences (NASDAQ:GILD) CEO Sells $2,546,100.00 in Stock - Daily Political

Gilead (GILD) Stock Fair Value Edges Higher After Analyst Target Increases

US approves cheap generic version of breakthrough HIV prevention jab - in major step towards ending Aids

Dr Reddy's gets USFDA nod for generic twice-a-year HIV prevention shot

20,862 Gilead Sciences, Inc. $GILD Shares Sold by Vise Technologies Inc.

Gilead Sciences, Inc. $GILD Shares Sold by Hennessy Advisors Inc. - Markets Daily

Medical Stocks To Keep An Eye On - November 2nd - Daily Political

189,152 Gilead Sciences, Inc. $GILD Shares Purchased by Bank Julius Baer & Co. Ltd Zurich

Gilead Sciences, Inc. $GILD Stock Sold by Hennessy Advisors Inc. - Stock Observer

Gilead Sciences, Inc. $GILD Holdings Decreased by Vise Technologies Inc. - Daily Political

Promising Healthcare Stocks To Research - November 1st - Markets Daily

Did Earnings Beat Just Shift Gilead Sciences (GILD) Investment Narrative?

Gilead Sciences, Inc. $GILD Stock Acquired by Sumitomo Mitsui Trust Group Inc.

Mirae Asset Global Investments Co. Ltd. Purchases 1,050,244 Shares of Gilead Sciences, Inc. $GILD

Gilead Sciences, Inc. $GILD Shares Sold by ProShare Advisors LLC

Mirae Asset Global Investments Co. Ltd. Buys New Stake in Gilead Sciences, Inc. $GILD - Stock Observer

4,837 Gilead Sciences, Inc. $GILD Shares Acquired by Summit Global Investments - Stock Observer

Gilead Sciences, Inc. $GILD Stake Trimmed by ProShare Advisors LLC - Daily Political

Gilead Sciences (NASDAQ:GILD) Issues Quarterly Earnings Results - Zolmax

Promising Pharmaceutical Stocks To Follow Today - October 31st - Stock Observer

Gilead Sciences, Inc. $GILD Shares Sold by VIRGINIA RETIREMENT SYSTEMS ET Al - Zolmax

VIRGINIA RETIREMENT SYSTEMS ET Al Sells 507,868 Shares of Gilead Sciences, Inc. $GILD - Markets Daily

Gilead Sciences (NASDAQ:GILD) Given New $183.00 Price Target at Morgan Stanley - Markets Daily

241,080 Gilead Sciences, Inc. $GILD Shares Acquired by International Assets Investment Management LLC

Gilead Sciences (NASDAQ:GILD) Posts Quarterly Earnings Results, Beats Estimates By $0.36 EPS - Stock Observer

Truist Financial Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price

Gilead Adjusts 2026 Sales Forecast Amid Medicare Price Cuts for Biktarvy, ETPharma

Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Citigroup - Daily Political

Gilead (GILD) Stock Rallies As Q3 Results Fuel HIV Growth Debate

JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead's Inflammation Pipeline Could Extend Its Moat Beyond HIV and Oncology | Morningstar

Citigroup Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

Scotiabank Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Morgan Stanley Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) Given New $181.00 Price Target at Truist Financial

Gilead Sciences (NASDAQ:GILD) Given New $190.00 Price Target at Wells Fargo & Company

Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Royal Bank Of Canada

Scotiabank Issues Positive Forecast for Gilead Sciences (NASDAQ:GILD) Stock Price - Stock Observer

Biotech Stocks To Keep An Eye On - October 30th

Gilead Sciences (NASDAQ:GILD) Stock Gets Price Target Boost from JPMorgan Chase & Co. - Daily Political

Gilead Sciences (NASDAQ:GILD) Stock Price Expected to Rise, Truist Financial Analyst Says - Stock Observer

What Does Gilead Sciences (GILD) Gain From Its Canada Deal And $45 Million Settlement?

Gilead Sciences, Inc. (NASDAQ:GILD) Shareholders to Collect $0.82 Quarterly Dividend

Cantor Fitzgerald Forecasts Strong Price Appreciation for Gilead Sciences (NASDAQ:GILD) Stock

Gilead Sciences (NASDAQ:GILD) Stock Price Target Raised at Needham & Company LLC

Global pharma giants to showcase cutting-edge innovations at 9th CIIE

Gilead Sciences, Inc. $GILD Shares Bought by China Universal Asset Management Co. Ltd.

Gilead Sciences (NASDAQ:GILD) Releases Quarterly Earnings Results, Beats Estimates By $0.36 EPS

What Gilead Sciences (GILD) Said on Its Q3 Earnings Call

Gilead Sciences (GILD) Q3 2026 Earnings Results & Call Transcript

Gilead Sciences (NASDAQ:GILD) surprises with Q3 2026 sales, full-year outlook slightly exceeds expectations

Gilead hikes 2026 sales outlook, says Medicare cuts Biktarvy price by 38% starting in 2028

Cognizant Q3 2026 Revenue Rises 4.6% to $5.66 Billion as AI, Banking and Cloud Deals Drive Growth

Gilead Sciences Inc. Announces Retreat In Q3 Income

Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength | Morningstar

Gilead Sciences Q3 26 Earnings Conference Call At 4:30 PM ET

Gilead Sciences, Inc. $GILD Holdings Lowered by Conning Inc.

Gilead Sciences, Inc. $GILD Shares Acquired by Bokf Na

Triple Negative Breast Cancer Market Size in the 7MM is projected to grow at a CAGR of 13.3% over the forecast period of 2026-2036 | DelveInsight | ABNewswire

5-year outcomes of chemotherapy de-escalation in HER2-positive early breast cancer and exploratory circulating tumor DNA analyses from the randomized phase 2 PHERGain trial

3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead

Gilead Sciences (NASDAQ:GILD) Reaches New 52-Week High - Here's What Happened - Daily Political

3,973 Shares in Gilead Sciences, Inc. $GILD Bought by Leo Wealth LLC - Stock Observer

Gilead buys oral IL-23R inhibitor programme from China's PepStar for $1.27 B

Pharmaceutical Stocks To Research - October 27th - Zolmax

Gilead (GILD) Stock Could Be 50% Undervalued On New Oncology Trial News

Biotech Stocks To Watch Now - October 27th - Markets Daily

Gilead expands in I&I with $1.28B Pepstar deal for oral IL-23Ri